Argos Therapeutics, Inc.

Argos Therapeutics, Inc.

Argos Therapeutics, Inc.

Date Founded



4233 Technology Drive, Durham, NC, 27704, USA

Type of Company


Employees (Worldwide)

101 - 250


Pension Funds & Sovereign Wealth
Hospitals & Patient Services
Medical Support Services

Company Description

Argos Therapeutics, Inc. is a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and is headquartered in Durham, NC.

Contact Data
Trying to get in touch with decision makers at Argos Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Vice President, Finance & Chief Accounting Officer

Chief Operating Officer

Chief Restructuring Officer

Director Quality Assurance



Senior Manager


Production Manager

Board of Directors

Adjunct Professor of Business Management & Marketing at The University of North Carolina at Wilmington

Chief Executive Officer at Veset International Ltd.

Paths to Argos Therapeutics, Inc.
Potential Connections via
Relationship Science
Argos Therapeutics, Inc.
Recent Transactions
Details Hidden

Argos Therapeutics, Inc. issued USD Common Stock

Details Hidden

Argos Therapeutics, Inc. issued USD Common Stock

Details Hidden

Argos Therapeutics, Inc. raised money in a private placement transaction

Transaction Advisors

Advised onArgos Therapeutics, Inc. issued USD Common Stock


Advised onArgos Therapeutics, Inc. issued USD Common Stock


Advised onArgos Therapeutics, Inc. issued USD Common Stock


Advised onArgos Therapeutics, Inc. issued USD Common Stock

Chief Compliance Officer

Advised onArgos Therapeutics, Inc. issued USD Common Stock

Legal Advisor

Advised onArgos Therapeutics, Inc. issued USD Common Stock

Advisors & Consultants
Pension Consultant

Altegris Advisors seeks to minimize investor risk while maximizing potential returns. The firm follows a disciplined process for identifying, evaluating, selecting, and monitoring investment talent across a spectrum of alternative strategies, including managed futures, global macro, long/short equity, event-driven, and others. The Investment Committee generally (i) performs an ongoing top-down strategy review to determine any potential opportunities for the lineup of strategies recommended by, or allocated to, by the firm and (ii) directs the Altegris Advisors’ research team as to a bottom-up approach to identify potential managers or strategies that may meet their performance objectives and investment strategy themes.

Pension Consultant
Pension Consultant

John Hancock Retirement Plan Services LLC offers service programs for retirement plans. The company is headquartered in Boston, MA.


Director of Antigen Discovery at Genzyme Corp.


Former Chief Financial & Business Officer at Viamet Pharmaceuticals Corp.


Professional at Berry & Company Public Relations


The University of North Carolina at Chapel Hill also known as UNC, UNC-Chapel Hill, Chapel Hill, North Carolina, or simply Carolina is a coeducational public research university located in Chapel Hill, North Carolina, United States. North Carolina has been consistently ranked among the highest ranked universities in the United States and is one of the original eight Public Ivy schools that provide an Ivy League experience for a public schooling price. After being chartered in 1789, the university first began enrolling students in 1795, which allows it to be one of three schools to claim the title of the oldest public university in the United States.

Green Cross Corp. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for blood, over the counter drugs, generals, vaccines, and others. The company was founded on November 1, 1969 and is headquartered in Yongin, South Korea.

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical. Its products include tumor drugs, antibacterial drugs, antifungal drugs, antiviral agent, digestive system agents, immune system agents, blood system agents, cardiovascular system agents, nervous system agents, electrolyte and acid-base balance and nutritional, liver disease auxiliary drugs, endocrinology system drugs, Chinese patent drugs, base large infusion, American ginseng and active pharmaceutical ingredients. The company was founded on September 6, 1999 and is headquartered in Chongqing, China.

Key Stats and Financials As of
Market Capitalization
Total Enterprise Value
Earnings Per Share
Details Hidden

DC Bio Corp. develops technology for application to cancer and diseases associated with chronic viral infections. The company is headquartered in Halifax, Canada.

Details Hidden

Intersouth Partners focuses on seed and early-stage investments in the information technology and life sciences sectors. They invest across the Southeastern US, primarily in the corridor from Baltimore through Florida, including Washington, DC, the Research Triangle region and Atlanta.

Details Hidden

Pharmstandard PJSC engages in the production and wholesale distribution of pharmaceutical and medical products. It operates through the following segments: Production and Wholesale of Pharmaceutical Products, and Production and Wholesale of Medical Equipment. The company was founded on March 23, 2003 and is headquartered in Dologoprudny, Russia.

Details Hidden

Forbion is an active manager which invests in life sciences and biomedical technology companies developing world-class drugs and technologies in Northwest Europe and the Eastern Coast of the US. The firm focuses on companies that have innovative technologies and drug development programs with unique advantages over current treatments, including biomedical technologies with a focus on interventional cardiology.In Europe, Forbion tends to take the lead investor role, while in the US they prefer to be a co-lead investor or active syndicate member, making initial investments ranging from €1-€7 million, and reserving additional capital for follow-on investments. The firm prefers to invest in international syndicates with other dedicated Life Sciences investors that share their commitment to the business.Forbion generally takes a seat on the board of directors, constantly looking for opportunities to add value to their investee companies by sharing their knowledge base and experience, or by drawing on their network of international experts. They participate in strategic decision-making on issues ranging from preclinical development programs to evaluating business development opportunities and financial guidance.Forbion aims to select companies with an experienced management team, a strong capability to develop products, and which are responsive to the changing nature of the life sciences industry, believing that such companies are best-suited to successful exits in the form of trade sales and IPOs. For start-up companies which do not have an experienced management team in place, the firm insists that company founders are open to expanding the management, and one of their key strengths is helping to identify and attract talented managers.

Compagnie de Saint-Gobain SA Industrial Machinery & Manufacturing | Courbevoie, Fra

Compagnie de Saint-Gobain SA engages in the production and distribution of construction materials. It operates through the following business segments: Innovative Materials, Construction Products, and Building Distribution. The Innovative Materials segment offers a unique portfolio of materials and processes for the habitat and industrial markets. The Construction Products segment offers interior and exterior solutions to enhance the comfort of buildings and homes, including plaster, acoustic and thermal insulation, wall facing, roofing and pipe systems. The Building Distribution segment serves the new building, renovation and home improvement markets. The company was founded in 1665 and is headquartered in Courbevoie, France.

Invetech Pty Ltd. Other Manufacturing | Melbourne, Australia

Invetech Pty Ltd. operates as an engineering consultancy firn. It specializes in product design, instrument development, and contract manufacturing in the healthcare markets. The firm's capabilities include fluidics, optics, motion, thermal control, consumable, industrial, experience and cartridge design, connectivity and systems integration, and quality systems. The company is headquartered in Melbourne, Australia.

Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Exelixis, Inc. Biotechnology - South San Francisco, CA

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. In advancing our first product, COMETRIQ, from discovery to market, we have established an effective and integrated infrastructure that encompasses the entire biopharmaceutical development continuum. We are committed to excellence in all aspects of our work and are dedicated to improving the care and outcome of cancer patients.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Argos Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Argos Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Argos Therapeutics, Inc..